Therapeutic options to further lower C-reactive protein for patients on statin treatment

Parag H. Joshi, Terry A. Jacobson

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Cardiovascular disease remains the leading cause of morbidity and mortality in developed nations. Inflammation plays an increasingly important role in the cardiovascular disease process. Recent statin trials have demonstrated a correlation between the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) and cardiovascular risk. This review describes the results of changes in hsCRP in the major statin outcome trials and the concept of a "dual target" for both low-density lipoprotein cholesterol and hsCRP. The effect on hsCRP of combination statin therapy with ezetimibe, fenofibric acid, niacin, and colesevelam is reviewed. Although some statin combination therapies have additional effects on CRP and other atherogenic lipids, evidence for their effect on cardiovascular risk beyond statin monotherapy is lacking. Ongoing placebo-controlled trials investigating statin combination therapy versus statin monotherapy may provide additional clues to the role of additional changes in lipids versus markers of inflammation on cardiovascular risk reduction. Until these trials are completed, current evidence suggests focusing on lowdensity lipoprotein cholesterol targets.

Original languageEnglish (US)
Pages (from-to)34-42
Number of pages9
JournalCurrent Atherosclerosis Reports
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
C-Reactive Protein
Therapeutics
Cardiovascular Diseases
Inflammation
Lipids
Niacin
Risk Reduction Behavior
Developed Countries
LDL Cholesterol
Biomarkers
Placebos
Morbidity
Mortality

Keywords

  • C-reactive protein
  • Ezetemibe
  • Fibrates
  • HsCRP
  • Niacin
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Therapeutic options to further lower C-reactive protein for patients on statin treatment. / Joshi, Parag H.; Jacobson, Terry A.

In: Current Atherosclerosis Reports, Vol. 12, No. 1, 01.01.2010, p. 34-42.

Research output: Contribution to journalReview article

@article{df0a9f16f4c54c5db766e9930eae3eb1,
title = "Therapeutic options to further lower C-reactive protein for patients on statin treatment",
abstract = "Cardiovascular disease remains the leading cause of morbidity and mortality in developed nations. Inflammation plays an increasingly important role in the cardiovascular disease process. Recent statin trials have demonstrated a correlation between the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) and cardiovascular risk. This review describes the results of changes in hsCRP in the major statin outcome trials and the concept of a {"}dual target{"} for both low-density lipoprotein cholesterol and hsCRP. The effect on hsCRP of combination statin therapy with ezetimibe, fenofibric acid, niacin, and colesevelam is reviewed. Although some statin combination therapies have additional effects on CRP and other atherogenic lipids, evidence for their effect on cardiovascular risk beyond statin monotherapy is lacking. Ongoing placebo-controlled trials investigating statin combination therapy versus statin monotherapy may provide additional clues to the role of additional changes in lipids versus markers of inflammation on cardiovascular risk reduction. Until these trials are completed, current evidence suggests focusing on lowdensity lipoprotein cholesterol targets.",
keywords = "C-reactive protein, Ezetemibe, Fibrates, HsCRP, Niacin, Statins",
author = "Joshi, {Parag H.} and Jacobson, {Terry A.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/s11883-009-0075-x",
language = "English (US)",
volume = "12",
pages = "34--42",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Therapeutic options to further lower C-reactive protein for patients on statin treatment

AU - Joshi, Parag H.

AU - Jacobson, Terry A.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Cardiovascular disease remains the leading cause of morbidity and mortality in developed nations. Inflammation plays an increasingly important role in the cardiovascular disease process. Recent statin trials have demonstrated a correlation between the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) and cardiovascular risk. This review describes the results of changes in hsCRP in the major statin outcome trials and the concept of a "dual target" for both low-density lipoprotein cholesterol and hsCRP. The effect on hsCRP of combination statin therapy with ezetimibe, fenofibric acid, niacin, and colesevelam is reviewed. Although some statin combination therapies have additional effects on CRP and other atherogenic lipids, evidence for their effect on cardiovascular risk beyond statin monotherapy is lacking. Ongoing placebo-controlled trials investigating statin combination therapy versus statin monotherapy may provide additional clues to the role of additional changes in lipids versus markers of inflammation on cardiovascular risk reduction. Until these trials are completed, current evidence suggests focusing on lowdensity lipoprotein cholesterol targets.

AB - Cardiovascular disease remains the leading cause of morbidity and mortality in developed nations. Inflammation plays an increasingly important role in the cardiovascular disease process. Recent statin trials have demonstrated a correlation between the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) and cardiovascular risk. This review describes the results of changes in hsCRP in the major statin outcome trials and the concept of a "dual target" for both low-density lipoprotein cholesterol and hsCRP. The effect on hsCRP of combination statin therapy with ezetimibe, fenofibric acid, niacin, and colesevelam is reviewed. Although some statin combination therapies have additional effects on CRP and other atherogenic lipids, evidence for their effect on cardiovascular risk beyond statin monotherapy is lacking. Ongoing placebo-controlled trials investigating statin combination therapy versus statin monotherapy may provide additional clues to the role of additional changes in lipids versus markers of inflammation on cardiovascular risk reduction. Until these trials are completed, current evidence suggests focusing on lowdensity lipoprotein cholesterol targets.

KW - C-reactive protein

KW - Ezetemibe

KW - Fibrates

KW - HsCRP

KW - Niacin

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=77149167583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149167583&partnerID=8YFLogxK

U2 - 10.1007/s11883-009-0075-x

DO - 10.1007/s11883-009-0075-x

M3 - Review article

C2 - 20425269

AN - SCOPUS:77149167583

VL - 12

SP - 34

EP - 42

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 1

ER -